Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity
12 March 2019
13 July 2019
06 October 2019 (online)
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy (TMA) characterized by the severe deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity (< 10%). Rapid ADAMTS13 testing is crucial for an early diagnosis and optimal management of acute TTP. We evaluated the performance of the HemosIL AcuStar ADAMTS13 activity assay (Instrumentation Laboratory, Bedford, Massachusetts, United States), a fully automated chemiluminescent immunoassay with an analytical time of 33 minutes. A method comparison study was performed on 176 samples from 49 healthy donors and 127 TMA patients (109 TTP, 7 atypical hemolytic uremic syndrome, 11 other TMAs), comparing this new assay with an in-house FRETS-VWF73 assay and a commercial enzyme-linked immunosorbent assay (ELISA) (TECHNOZYM ADAMTS-13 Activity, Technoclone GmbH, Vienna, Austria). Agreement between methods was assessed with focus on ADAMTS13 activity less than 10%, the medical decision level relevant for TTP diagnosis. The HemosIL AcuStar ADAMTS13 Activity showed good correlation with both the FRETS-VWF73 (r = 0.96) and ELISA (r = 0.96) methods. Slope of the Passing–Bablok regression was 1.05 for FRETS-VWF73 and 1.02 for ELISA, and absolute bias at the medical decision level was +0.1 and +0.3%, respectively. The study also revealed high agreement with FRETS-VWF73 (kappa 0.97) and ELISA (kappa 0.98) methods in classifying TTP patients with a severe deficiency of ADAMTS13 activity. Because of its short turnaround time and full automation, the HemosIL AcuStar ADAMTS13 activity assay might become the assay of choice to rapidly test ADAMTS13 activity in plasma and thus establish the diagnosis of acute TTP in emergency settings.
KeywordsADAMTS/ADAMTS13 - thrombotic thrombocytopenic purpura (TTP/HUS) - diagnosis management - autoimmune diseases - chemiluminescent assay
C.V. designed the study, performed experiments, performed quality control, interpreted the results, and wrote the manuscript. M.M. developed the HemosIL AcuStar ADAMTS13 Activity assay, designed the study, performed quality control, interpreted the results, and wrote the manuscript. I.M. designed the study, interpreted the results, and critically reviewed the manuscript. M.B. collected clinical and/or experimental data and performed experiments and critically reviewed the manuscript. L.S. collected clinical and/or experimental data and critically reviewed the manuscript. S.F. designed the study, analyzed and interpreted the results, and critically reviewed the manuscript. D.M.-P. designed the study, analyzed and interpreted the results, and critically reviewed the manuscript. D.G. designed the study, interpreted the results, and critically reviewed the manuscript. J.S.-D. interpreted the results and critically reviewed the manuscript. S.B. developed the HemosIL AcuStar ADAMTS13 Activity assay, collected experimental data, and critically reviewed the manuscript. S.M.T. enrolled patients, and critically reviewed the manuscript. L.F. enrolled patients and critically reviewed the manuscript. E.R. enrolled patients and critically reviewed the manuscript. F.P. designed the study, enrolled patients, interpreted the results, and critically reviewed the manuscript. All authors approved the final version of the manuscript.
- 1 Scully M, Cataland S, Coppo P. , et al; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017; 15 (02) 312-322
- 2 Connell NT, Cheves T, Sweeney JD. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura. Transfusion 2016; 56 (02) 354-359
- 3 Mirabet M, Blanch S, Puig J, Serra J. Highly sensitive fully automated chemiluminescent immunoassay for rapid quantification of ADAMTS13 activity. Res Pract Thromb Haemost 2017; 1 (Suppl. 01) 1297
- 4 Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006; 46 (08) 1444-1452
- 5 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129 (01) 93-100
- 6 Mancini I, Valsecchi C, Lotta LA. , et al. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thromb Haemost 2014; 112 (02) 297-303
- 7 Favresse J, Lardinois B, Chatelain B, Jacqmin H, Mullier F. Evaluation of the fully automated HemosIL Acustar ADAMTS13 Activity assay. Thromb Haemost 2018; 118 (05) 942-944
- 8 Scully M, Cataland SR, Peyvandi F. , et al; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380 (04) 335-346